The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update

Bibliography

• Kaufman DW, Kelly JP, Rosenberg L, Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002;287:337-44
   PubMed Web of Science ®Google Scholar
• Sloan RW. Drug interactions. Am Fam Physician 1983;6:229-38
   Google Scholar
• Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38:666-71
   PubMed Web of Science ®Google Scholar
• Bjorkman IK, Fastbom J, Schmidt IK, ; Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother 2002;36:1675-81
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003;192:23-32
   PubMed Web of Science ®Google Scholar
• Bachmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 2005;39:1064-72
   PubMed Web of Science ®Google Scholar
• Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998;12:485-94
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – toward a consensus. Pharm Res 2001;18:1071-80
   PubMedGoogle Scholar
• Boobis A, Watelet JB, Whomsley R, Drug interactions. Drug Metab Rev 2009;41:486-527
   PubMed Web of Science ®Google Scholar
• Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 2002;127:279-84
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005;78:582-92
   PubMed Web of Science ®Google Scholar
• Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-8
   PubMed Web of Science ®Google Scholar
• Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21
   PubMed Web of Science ®Google Scholar
• Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci 2006;95:2778-87
   PubMed Web of Science ®Google Scholar
• Palatini P, De Martin S, Pegoraro P, Orlando R. Enzyme inhibition and induction in liver disease. Curr Clin Pharmacol 2008;3:56-69
   PubMedGoogle Scholar
• Lee LS, Nafziger AN, Bertino JS. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005;78:1-6
   PubMed Web of Science ®Google Scholar
• Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995;29:370-91
   PubMed Web of Science ®Google Scholar
• Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51
   PubMed Web of Science ®Google Scholar
• Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver diseases. J Hepatol 1997;26(Suppl 2):63-72
   PubMedGoogle Scholar
• Delco F, Tchambaz L, Schlienger R, Dose adjustment in patients with liver disease. Drug Saf 2005;28:529-45
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
   PubMed Web of Science ®Google Scholar
• Pauley JL, Panetta JC, Schmidt J, Late-onset delayed excretion of methotrexate. Cancer Chemother Phamacol 2004;54:146-52
   PubMed Web of Science ®Google Scholar
• Dickgreber NJ, Sorensen JB, Paz-Ares LG, Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 2010;16:2872-80
   PubMed Web of Science ®Google Scholar
• Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981;1:673-6
   PubMedGoogle Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
   PubMed Web of Science ®Google Scholar
• Kawasaki S, Imamura H, Bandai Y, Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology 1992;102:1351-5
   PubMed Web of Science ®Google Scholar
• Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001;2:165-83
   PubMed Web of Science ®Google Scholar
• Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004;5:157-67
   PubMed Web of Science ®Google Scholar
• Orlando R, Piccoli P, De Martin S, Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004;75:80-8
   PubMed Web of Science ®Google Scholar
• Orlando R, Padrini R, Perazzi M, Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 2006;79:489-99
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, Fraser R, Hilmer S, The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005;44:187-200
   PubMed Web of Science ®Google Scholar
• Gariepy L, Fenyves D, Kassissia I, Villeneuve JP. Clearance by the liver in cirrhosis. II. characterization of propranolol uptake with the multiple-indicator dilution technique. Hepatology 1993;18:823-31
   PubMed Web of Science ®Google Scholar
• McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991;21:42-69
   PubMed Web of Science ®Google Scholar
• Hickey PL, Angus PW, McLean AJ, Morgan DJ. Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats. Gastroenterology 1995;108:1504-9
   PubMed Web of Science ®Google Scholar
• Froomes PR, Morgan DJ, Smallwood RA, Angus PW. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology 1999;116:915-20
   PubMed Web of Science ®Google Scholar
• MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors, Applied Pharmacokinetics and Pharmacodynamics. Williams and Wilkins, Philadelphia, Lippincott; 2006. p. 82
   Google Scholar
• Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
   PubMed Web of Science ®Google Scholar
• Susla GM, Atkinson AJ. Effect of liver disease on pharmacokinetics. In: Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP, editors, Principles of clinical pharmacology. Academic Press, San Diego (CA); 2007. p. 73
   Google Scholar
• Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 1995;12:227-33
   PubMed Web of Science ®Google Scholar
• Toutain PL, Bousquet-Melou A. Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther 2002;25:460-3
   PubMed Web of Science ®Google Scholar
• Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes. Int J Mol Med 1999;3:227-38
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430
   PubMed Web of Science ®Google Scholar
• Koley AP, Robinson RC, Markowitz A, Friedman FK. Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 1997;53:455-60
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
   PubMed Web of Science ®Google Scholar
• Hasler JA, Estabrook R, Murray M, Human cytochromes P450. Mol Aspects Med 1999;20:1-137
   Google Scholar
• Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009;85:434-8
   PubMed Web of Science ®Google Scholar
• De Martin S, Orlando R, Bertoli M, Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther 2006;80:597-606
   PubMed Web of Science ®Google Scholar
• Orlando R, De Martin S, Andrighetto L, Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. Br J Clin Pharmacol 2010;69:279-86
   PubMed Web of Science ®Google Scholar
• Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983;3:913-8
   PubMed Web of Science ®Google Scholar
• Wang JS, Backman JT, Taavitsainen P, Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000;28:959-65
   PubMed Web of Science ®Google Scholar
• Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977;296:1495-7
   PubMed Web of Science ®Google Scholar
• Pieper JA, Johnson KE. Lidocaine. In: Evans WE, Schentag JJ, Jusko WJ, editors, Applied pharmacokinetics. Applied Therapeutics, Inc., Vancouver (WA); 1992
   Google Scholar
• Fixley M, Shen DD, Azarnoff DL. Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis 1977;115:955-62
   PubMed Web of Science ®Google Scholar
• Hendeles L, Weinberger M, Bighley L. Absolute bioavailability of oral theophylline. Am J Hosp Pharm 1977;34:525-7
   PubMedGoogle Scholar
• Crowley JJ, Cusack BJ, Jue SG, Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 1988;245:513-23
   PubMed Web of Science ®Google Scholar
• Loi CM, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997;280:627-37
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-10
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. Mechanism-based inactivation of human cytochrome P450 enzymes: Strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 2007;37:1225-56
   PubMed Web of Science ®Google Scholar
• Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 2010;125:230-48
   PubMed Web of Science ®Google Scholar
• Andersen V, Pedersen N, Larsen NE, Intestinal first pass metabolism of midazolam in liver cirrhosis – effect of grapefruit juice. Br J Clin Pharmacol 2002;54:120-4
   PubMed Web of Science ®Google Scholar
• Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989;46:521-7
   PubMed Web of Science ®Google Scholar
• Orlando R, Piccoli P, De Martin S, Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 2003;55:86-93
   PubMed Web of Science ®Google Scholar
• Chambers HF. Macrolides (erythromycin, clarithromycin and azithromycin). In: Brunton LL, Lazo JS, Parker KL, editors, Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York; 2006. p. 1182
   Google Scholar
• Orlando R, De Martin S, Pegoraro P, Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 2009;85:319-26
   PubMed Web of Science ®Google Scholar
• Christensen M, Andersson K, Dalen P, The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003;73:517-28
   PubMed Web of Science ®Google Scholar
• Mirghani RA, Ericsson O, Tybring G, Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol 2003;59:23-8
   PubMed Web of Science ®Google Scholar
• Wanwimolruk S, Paine MF, Pusek SN, Watkins PB. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol 2002;54:643-51
   PubMed Web of Science ®Google Scholar
• Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996;30:263-99
   PubMed Web of Science ®Google Scholar
• Barry M, Keeling PW, Weir D, Feely J. Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine. Clin Pharmacol Ther 1990;47:366-70
   PubMed Web of Science ®Google Scholar
• Routledge PA. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986;22:499-506
   PubMed Web of Science ®Google Scholar
• Hung DY, Chang P, Cheung K, Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 2002;301:1079-87
   PubMed Web of Science ®Google Scholar
• FDA Guidance for Industry. Drug interactions studies, data analysis and implications for dosing and labelling 2006. Available from: http://www.fda.gov/cder, http://fda.cderguidance/6695dft.pdf. [Last accessed 9 March 2010]
   Google Scholar
• Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: The relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 2006;163:1891-6
   PubMed Web of Science ®Google Scholar